Double attack on tough bladder cancers shows promise

This small pilot study tested whether combining an immunotherapy drug (pembrolizumab) with a specific chemotherapy regimen before surgery could better treat muscle-invasive bladder cancers with unusual cell types. The goal was to see if this combination could shrink or eliminate the tumor more effectively than chemotherapy alone, potentially improving outcomes for patients with these rare and aggressive variants. Seventeen eligible patients received the treatment and were monitored for tumor response and side effects.